5 Amendments of Ignazio CORRAO related to 2016/2057(INI)
Amendment 34 #
Draft opinion
Paragraph 2
Paragraph 2
2. Urges not to use free trade agreements with low- and middle-income countries (LMICs) to introduce TRIPS- plus intellectual property (IP) rules that extend monopoly protection, and not to introduce new IP enforcement rules or investment protection to the detriment of access to quality medicines;
Amendment 46 #
Draft opinion
Paragraph 3
Paragraph 3
3. Supports competition in generic medicines, which allows broad access to medicines in LMICs; calls, in particular, for the EU to support actively governments that use the available legal measures, including TRIPS safeguards and flexibilities, to protect and promote public health; calls also for the EU to immediately stop targeting countries such as India that have implemented progressive TRIPS- compliant IP policies which promote access to quality controlled medicines, through its watch-list of ‘priority countries’;
Amendment 70 #
Draft opinion
Paragraph 5
Paragraph 5
5. Urges to take advantage of the ongoing review process of the EU Tiered Pricing Regulation to repeal it unless it can be amended, in close collaboration and transparent discussion with the Commission’s Directorates-General for International Cooperation and Development (DG DEVCO) and for Health and Food Safety (DG SANTÉ), in order to support all measures that countries have at their disposal to ensure affordable access to medicines.;
Amendment 71 #
Draft opinion
Paragraph 5
Paragraph 5
5. Urges to take advantage of the ongoing review process of the EU Tiered Pricing Regulation to repeal it unless it can be amended, in close collaboration with the Commission’s Directorates-General for International Cooperation and Development (DG DEVCO) and for Health and Food Safety (DG SANTÉ), in order to support all measures that countries have at their disposal to ensure affordable access to quality controlled medicines.;
Amendment 79 #
Draft opinion
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Calls on the Commission to implement the principle of delinkage in its research funding whereby the costs of research and development (R&D) is separated from the end price of the product, and implementing the guiding R&D principles adopted by all Member States at the WHO namely that R&D should be needs-driven and ensure affordability, effectiveness, efficiency and equity;